CA2248350A1 - Inhibition of proliferation of cells - Google Patents

Inhibition of proliferation of cells Download PDF

Info

Publication number
CA2248350A1
CA2248350A1 CA002248350A CA2248350A CA2248350A1 CA 2248350 A1 CA2248350 A1 CA 2248350A1 CA 002248350 A CA002248350 A CA 002248350A CA 2248350 A CA2248350 A CA 2248350A CA 2248350 A1 CA2248350 A1 CA 2248350A1
Authority
CA
Canada
Prior art keywords
egr
expression
cells
mrna
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248350A
Other languages
English (en)
French (fr)
Inventor
Levon Khachigian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2248350A1 publication Critical patent/CA2248350A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002248350A 1996-03-07 1997-03-07 Inhibition of proliferation of cells Abandoned CA2248350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN8554A AUPN855496A0 (en) 1996-03-07 1996-03-07 Prevention of proliferation of vascular cells
AUPN8554 1996-03-07

Publications (1)

Publication Number Publication Date
CA2248350A1 true CA2248350A1 (en) 1997-09-12

Family

ID=3792866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248350A Abandoned CA2248350A1 (en) 1996-03-07 1997-03-07 Inhibition of proliferation of cells

Country Status (7)

Country Link
US (1) US6200960B1 (enExample)
EP (1) EP0934404A4 (enExample)
JP (1) JP2000506725A (enExample)
AU (1) AUPN855496A0 (enExample)
CA (1) CA2248350A1 (enExample)
WO (1) WO1997032979A1 (enExample)
ZA (1) ZA972000B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
HRP20000832A2 (en) * 1998-06-02 2001-04-30 Glaxo Group Ltd Gene therapy method
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
AUPQ367699A0 (en) * 1999-10-26 1999-11-18 Unisearch Limited Treatment of cancer
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
EP1263484B1 (en) * 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Coating which promotes endothelial cell adherence
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
WO2003060516A1 (en) * 2002-01-10 2003-07-24 Takeda Chemical Industries, Ltd. Screening method
EP1489971A2 (en) * 2002-04-03 2004-12-29 Jackie R. See Methods for ultrasonic imaging and treating diseased tissues
CA2490490A1 (en) * 2002-07-03 2004-01-15 Quelis Id Systems Inc. Wire positioning and mechanical attachment for a radio-frequency identification device
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
DE10355511A1 (de) * 2003-11-24 2005-06-09 Biotronik Gmbh & Co. Kg Endovasculäres Implantat mit einer aktiven Beschichtung
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
ES2986867T3 (es) * 2005-03-03 2024-11-12 Mirus Llc Aleaciones metálicas mejoradas para dispositivos médicos
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
WO2007118157A1 (en) * 2006-04-05 2007-10-18 Joslin Diabetes Center, Inc. Enhancing stem cell mobilization
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
WO2015199816A1 (en) 2014-06-24 2015-12-30 Icon Medical Corp. Improved metal alloys for medical devices
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes

Also Published As

Publication number Publication date
ZA972000B (en) 1997-10-24
EP0934404A1 (en) 1999-08-11
JP2000506725A (ja) 2000-06-06
EP0934404A4 (en) 2002-08-07
WO1997032979A1 (en) 1997-09-12
US6200960B1 (en) 2001-03-13
AUPN855496A0 (en) 1996-04-04

Similar Documents

Publication Publication Date Title
US6200960B1 (en) Inhibition of proliferation of cells
JP7174384B2 (ja) キメラ２重鎖核酸
JP3316216B2 (ja) 安定化外部ガイド配列
US6566127B1 (en) Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
CA2012312C (en) Genetic units for inhibiting the function of rna
EP2327781A1 (en) Micro-RNA and tissue repair
Santiago et al. Vascular Smooth Muscle Cell Proliferation and Regrowth after Mechanical Injury in Vitro Are. Egr-1/NGFI-A-Dependent
US20120270930A1 (en) Methods and compositions for dysferlin exon-skipping
KR20080031164A (ko) ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
CA3059497A1 (en) Antisense compounds targeted to connexins and methods of use thereof
Tonkinson et al. New Drugs: Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents
WO2002057480A2 (en) Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
Alt et al. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation
Fahmy et al. Antisense Egr‐1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury
WO2000032765A9 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
WO1996018733A2 (en) Ribozyme-mediated inactivation of leukemia-associated rna
WO2001012789A2 (en) APOLIPOPROTEIN B mRNA-SPECIFIC RIBOZYME
US20040220131A1 (en) Method for treatment of cancerous angiogenic disorders
KR20010112857A (ko) 촉매성 분자
US20040072783A1 (en) Nucleozymes with endonuclease activity
AU707943B2 (en) Inhibition of proliferation of cells
US20040072768A1 (en) Inhibition of proliferation of cells
JP2003512442A (ja) 癌の治療法
Labialle et al. Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope?
D ‘Orléans-Juste et al. DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued